BMP-7: Therapeutic target for ocular fibrotic disorders

Bioscience hypotheses Pub Date : 2009-01-01 DOI:10.1016/j.bihy.2009.02.012

Jun-Yi Wang, Guo-ge Han, Jing Wang, Hai-Feng Mei, An-Huai Yang

{"title":"BMP-7: Therapeutic target for ocular fibrotic disorders","authors":"Jun-Yi Wang, Guo-ge Han, Jing Wang, Hai-Feng Mei, An-Huai Yang","doi":"10.1016/j.bihy.2009.02.012","DOIUrl":null,"url":null,"abstract":"<div><p>Scarring of cornea, glaucoma, after-cataract and also proliferative vitreoretinopathy(PVR) related tractional retina detachment, age related macular degeneration and diabetic retinopathy etc., which are the major and seriously impair vision diseases in eyes, with various appearance and different therapy method, but maybe they have the similar pathogenesis—fibrosis, and all the above ocular diseases can be regarded as fibrotic disorders. Thus inhibition of the fibrotic process may provide a potentially novel therapeutic approach to the treatment of these ocular diseases mentioned above. Now numerous studies have proved that BMP-7 significantly reversed renal, hepatic, pulmonary fibrosis, including inhibition of Transforming growth factor-<em>β</em> (TGF-<em>β</em>) production, suppression of epithelial-to-mesenchymal transition (EMT), and repair of severely damaged epithelial cells. So it is reasonable to refer that BMP-7 may have the same preventive effect in these ocular fibrotic disorders. A potential clinical therapy can be developed by using the anti-fibrosis effect of BMP-7.</p></div>","PeriodicalId":87894,"journal":{"name":"Bioscience hypotheses","volume":"2 6","pages":"Pages 413-416"},"PeriodicalIF":0.0000,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bihy.2009.02.012","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioscience hypotheses","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1756239209000718","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Scarring of cornea, glaucoma, after-cataract and also proliferative vitreoretinopathy(PVR) related tractional retina detachment, age related macular degeneration and diabetic retinopathy etc., which are the major and seriously impair vision diseases in eyes, with various appearance and different therapy method, but maybe they have the similar pathogenesis—fibrosis, and all the above ocular diseases can be regarded as fibrotic disorders. Thus inhibition of the fibrotic process may provide a potentially novel therapeutic approach to the treatment of these ocular diseases mentioned above. Now numerous studies have proved that BMP-7 significantly reversed renal, hepatic, pulmonary fibrosis, including inhibition of Transforming growth factor-β (TGF-β) production, suppression of epithelial-to-mesenchymal transition (EMT), and repair of severely damaged epithelial cells. So it is reasonable to refer that BMP-7 may have the same preventive effect in these ocular fibrotic disorders. A potential clinical therapy can be developed by using the anti-fibrosis effect of BMP-7.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

BMP-7:眼部纤维化疾病的治疗靶点

角膜瘢痕、青光眼、白内障后发以及增殖性玻璃体视网膜病变(PVR)相关的牵引性视网膜脱离、年龄相关性黄斑变性、糖尿病性视网膜病变等，是眼部主要的、严重损害视力的疾病，其外观各不相同，治疗方法也各不相同，但它们可能具有相似的发病机制-纤维化，上述眼部疾病均可视为纤维化性疾病。因此，抑制纤维化过程可能为上述眼部疾病的治疗提供一种潜在的新治疗方法。目前已有大量研究证明BMP-7能显著逆转肾、肝、肺纤维化，包括抑制转化生长因子-β (TGF-β)的产生，抑制上皮-间质转化(EMT)，修复严重受损的上皮细胞。因此，我们有理由认为BMP-7在这些眼部纤维化疾病中可能具有同样的预防作用。利用BMP-7的抗纤维化作用，可以开发一种潜在的临床治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Bioscience hypotheses

自引率

0.00%

发文量